Research
A contribution schedule and a lump sum take risk at different times
Dollar-cost averaging changes when cash becomes market exposure. Investing the same total at the start takes the market’s path immediately. Neither rule is a forecast, and neither is a theorem that wins on every path.
Key points
- The schedule changes timing. It does not, by arithmetic, beat a lump sum on a steadily rising path.
- Cash that is still waiting is not exposed, and it is also not earning the market return you might type into a calculator.
- Use the dollar-cost calculator with a return you assume. The label on the result is hypothetical.
What is going on
A schedule invests a similar amount on dates you choose, so the number of units changes with the price. A lump sum invests the cash you already have. If prices rise throughout, the lump sum bought more units at the early, lower prices. If prices fall throughout, the schedule bought more units later. A path that rises and then falls can favour either rule depending on the dates. Investor.gov discusses the role of costs and of a long holding period. It does not publish a winner between these two funding rules.
Why it matters
Cash drag is the gap between money that has arrived and money that has been invested. A schedule keeps that gap on purpose. That can reduce the loss if prices fall early, and it can reduce the gain if prices rise early. Costs apply to each purchase. A comparison that ignores the number of tickets is incomplete. The calculator on this site does not invent the path. You type the assumption.
What to watch
Write the dates, the amount, the fee and whether the cash earns anything while it waits. Separate a dividend, if one is declared, from the price path. A reinvested dividend is a new purchase at the price then available.
Risks
A long falling path hurts both rules. Borrowing to fund either rule adds a cost and a repayment that the price path does not owe you. Nothing on this page is a historical contest with a published winner.
What not to conclude
A single assumed compound rate, applied to both rules, is a picture of that rate. It is not evidence that one funding method beat the other in a real market. Change the rate or the fee and you are looking at a different picture.
Related
Sources and review
Written by: WiT Markets Editorial. Writes and structures WiT Markets pages. Separates a sourced fact from a cell that is Not confirmed.
Review: Editorially reviewed. This is not a qualified specialist review and it is not a legal sign-off.
Last reviewed: . Next review due . The date is an editorial pass. It is not a live check of every third-party fee.
Regulatory and official sources
- Investor.gov — checked 13 October 2026
Other sources
- WiT Markets methodology — checked 13 October 2026
Methodology. Editorial policy. Corrections. Report an error.